Terms: = Bone cancer AND CLIP1, ENSG00000130779, 6249, P30622, RSN, MGC131604, CYLN1, CLIP170, CLIP-170, CLIP AND Clinical Outcome
2 results:
1. Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.
van Luijn MM; Chamuleau ME; Thompson JA; Ostrand-Rosenberg S; Westers TM; Souwer Y; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
Haematologica; 2010 Mar; 95(3):485-93. PubMed ID: 19903675
[TBL] [Abstract] [Full Text] [Related]
2. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome.
Chamuleau ME; Souwer Y; Van Ham SM; Zevenbergen A; Westers TM; Berkhof J; Meijer CJ; van de Loosdrecht AA; Ossenkoppele GJ
Cancer Res; 2004 Aug; 64(16):5546-50. PubMed ID: 15313888
[TBL] [Abstract] [Full Text] [Related]
